(HCM) HUTCHMED DRC - Ratings and Ratios

HUTCHMED (China) Limited, a biopharmaceutical company incorporated in 2000 and headquartered in Hong Kong, focuses on the discovery, development, and commercialization of innovative, targeted therapeutics and immunotherapies for cancer and immunological diseases. The company operates globally, with significant presence in Hong Kong, the United States, and other international markets. HUTCHMEDs pipeline includes a range of small molecule kinase inhibitors and other targeted therapies designed to address unmet medical needs in oncology and immunology.

The companys lead products include Fruquintinib, an oral vascular endothelial growth factor receptor (VEGFR) inhibitor approved for colorectal cancer (CRC) and under development for breast cancer, gastric cancer (GC), microsatellite stable-CRC, endometrial cancer (EMC), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). Savolitinib, a mesenchymal-epithelial transition (MET) inhibitor, is being developed for NSCLC, papillary RCC, and GC. Surufatinib, another key asset, targets pancreatic neuroendocrine tumors (NET), non-pancreatic NET, and pancreatic ductal adenocarcinoma. The pipeline also includes Sovleplenib for immune thrombocytopenic purpura and warm autoimmune hemolytic anemia, Tazemetostat for epithelioid sarcoma and follicular lymphoma, and Fanregratinib for intrahepatic cholangiocarcinoma. Ranosidenib, a dual inhibitor of IDH1 and IDH2 enzymes, is in development for acute myeloid leukemia (AML).

HUTCHMEDs early-stage pipeline includes HMPL-760, currently in Phase I/II trials for relapsed/refractory diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other B-cell non-Hodgkin lymphomas (B-NHL). HMPL-506 is being investigated for mixed-lineage leukemia-rearranged (MLL-r) and nucleophosmin 1-mutant (NPM1mut) AML. The company has established strategic collaborations with major pharmaceutical companies, including AstraZeneca, Lilly, Takeda, BeiGene, Inmagene Biopharmaceuticals, Innovent Biologics, and Epizyme.

Formerly known as Hutchison China MediTech Limited, the company adopted its current name, HUTCHMED (China) Limited, in May 2021. Its shares are listed on the NASDAQ under the ticker symbol HCM, with a market capitalization of approximately $2.35 billion as of the latest data. HUTCHMEDs research and development efforts are supported by a strong intellectual property portfolio and a focus on precision medicine.